Omnicell (NASDAQ:OMCL) Given a $55.00 Price Target at Piper Sandler

Omnicell (NASDAQ:OMCL) has been assigned a $55.00 target price by Piper Sandler in a research note issued to investors on Monday, MarketBeat reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective indicates a potential upside of 70.99% from the stock’s current price.

A number of other research firms have also recently weighed in on OMCL. Wells Fargo & Company upped their price target on Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, July 21st. Bank of America lifted their price objective on Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 23rd. Benchmark cut their price objective on Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, Wall Street Zen downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and an average price target of $46.71.

Omnicell Stock Up 2.2%

Shares of NASDAQ OMCL traded up $0.70 during mid-day trading on Monday, hitting $32.17. The company had a trading volume of 187,083 shares, compared to its average volume of 566,132. Omnicell has a 1-year low of $22.66 and a 1-year high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The company has a market capitalization of $1.48 billion, a PE ratio of 64.32, a price-to-earnings-growth ratio of 9.15 and a beta of 0.78. The business’s 50-day simple moving average is $29.44 and its 200 day simple moving average is $32.43.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. The company had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. During the same quarter last year, the company posted $0.51 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, analysts predict that Omnicell will post 1.09 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently added to or reduced their stakes in OMCL. Lazard Asset Management LLC boosted its position in Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after purchasing an additional 737,536 shares during the period. Toronto Dominion Bank acquired a new stake in shares of Omnicell in the 4th quarter valued at about $30,637,000. Dimensional Fund Advisors LP raised its stake in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock valued at $73,127,000 after purchasing an additional 394,820 shares in the last quarter. Oberweis Asset Management Inc. acquired a new stake in shares of Omnicell in the 4th quarter valued at about $14,834,000. Finally, Pacer Advisors Inc. acquired a new stake in shares of Omnicell in the 1st quarter valued at about $10,542,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.